{"id":"NCT03925727","sponsor":"Mimetogen Pharmaceuticals USA, Inc.","briefTitle":"Tavilermide Ophthalmic Solution for the Treatment of Dry Eye","officialTitle":"Multi-Center, Randomized,Double-Masked, Vehicle-Controlled Study to Assess the Safety and Efficacy Study of Tavilermide Ophthalmic Solutions for the Treatment of Dry Eye","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-03-28","primaryCompletion":"2020-06-11","completion":"2020-06-11","firstPosted":"2019-04-24","resultsPosted":"2023-03-09","lastUpdate":"2023-04-05"},"enrollment":623,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Keratoconjunctivitis Sicca","Dry Eye"],"interventions":[{"type":"DRUG","name":"Tavilermide ophthalmic solution","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"1% Tavilermide ophthalmic solution","type":"EXPERIMENTAL"},{"label":"5% Tavilermide ophthalmic solution","type":"EXPERIMENTAL"},{"label":"Vehicle ophthalmic solution","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the safety and efficacy of 5% tavilermide and 1% tavilermide ophthalmic solutions compared with placebo ophthalmic solution in treating the signs and symptoms of dry eye.","primaryOutcome":{"measure":"Change From Baseline in Eye Dryness Score as Measured by the VAS","timeFrame":"Baseline to Day 85 in 5% Tavilermide versus Placebo","effectByArm":[{"arm":"Tavilermide 5%","deltaMin":-15.1,"sd":1.64},{"arm":"Tavilermide 1%","deltaMin":-20.6,"sd":2.66},{"arm":"Placebo","deltaMin":-16.5,"sd":1.67}],"pValues":[{"comp":"OG000 vs OG002","p":"0.5533"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":8},"locations":{"siteCount":22,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":261},"commonTop":["Instillation site pain"]}}